Physician profile
Alexia Flangini
NPI 1023457181
$4,106.08
in general payments reported to CMS, 2019-2025
25 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $269 · 2021: $518 · 2022: $1,758 · 2023: $701 · 2024: $54.47 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $997.49 | 2019-2025 | Fintepla, Briviact |
| Livanova USA, INC. | $844.82 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $424.77 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $299.24 | 2019-2022 | |
| Neurelis, INC. | $258.41 | 2020-2025 | Valtoco |
| Greenwich Biosciences, INC. | $237.67 | 2019-2021 | |
| Eisai INC. | $177.44 | 2019-2023 | |
| Upsher-Smith Laboratories LLC | $127.34 | 2019-2025 | |
| Immedica Pharma US, INC. | $113.00 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $88.81 | 2023 | Aptiom |
| Zogenix INC. | $83.83 | 2021 | |
| Acadia Pharmaceuticals INC | $70.93 | 2023 | Daybue |
| Novartis Pharmaceuticals Corporation | $51.56 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $50.44 | 2023 | Fycompa |
| Abbvie INC. | $44.39 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $40.84 | 2023 | Eprontia, Zonisade |
| Genentech USA, INC. | $25.70 | 2023 | Evrysdi |
| Ns Pharma, INC. | $25.23 | 2023 | Viltepso |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $24.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.79 | 2022 | |
| Sk Life Science, INC. | $22.58 | 2025 | |
| Aucta Pharmaceuticals, INC. | $21.97 | 2025 | Motpoly Xr |
| Alexion Pharmaceuticals, INC. | $20.76 | 2025 | Koselugo |
| Medtronic, INC. | $17.85 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexia Flangini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.